Novel ofloxacin derivatives: Synthesis, antimycobacterial and toxicological evaluation

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 3, 2008, Pages 1229-1236

  Dinakaran, Murugesan ^a   Senthilkumar, Palaniappan ^a   Yogeeswari, Perumal ^a   China, Arnab ^b   Nagaraja, Valakunja ^b   Sriram, Dharmarajan ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

^b INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

Antimycobacterial activity; Oxazino 2,3,4 ij quinoline 6 carboxylic acids; Tuberculosis

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); OFLOXACIN; OXAZINOQUINOLONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG DESIGN; DRUG DETERMINATION; DRUG INHIBITION; DRUG POTENCY; DRUG SYNTHESIS; IC 50; IN VITRO STUDY; IN VIVO STUDY; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTIDRUG RESISTANCE; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; STRUCTURE ACTIVITY RELATION; THERAPY EFFECT; TOXICITY TESTING; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; ANTITUBERCULAR AGENTS; COMBINATORIAL CHEMISTRY TECHNIQUES; DNA GYRASE; ENZYME INHIBITORS; FLUOROQUINOLONES; LUNG; MICE; MOLECULAR STRUCTURE; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; SPLEEN; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA; BACTERIA (MICROORGANISMS); CORYNEBACTERINEAE; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS;

EID: 38749085659     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.11.110     Document Type: Article

References (18)

1. Shandil R.K., Jayaram R., Kaur P., Gaonkar S., Suresh B.L., Mahesh B.N., Jayashree R., Nandi V., Bharath S., and Balasubramanian V. Antimicrob. Agents Chemother. 51 (2007) 576
2. Nuermberger E.L., Yoshimatsu T., Tyagi S., O'Brien R.J., Vernon A.R., Chaisson R.E., Bishai W.R., and Grosset J.H. Am. J. Respir. Crit. Care Med. 169 (2004) 421
3. Veziris N., Truffot-Pernot C., Aubry A., Jarlier V., and Lounis N. Antimicrob. Agents Chemother. 47 (2003) 3117
4. Maxwell A. Trends Microbiol. 5 (1997) 102
5. Bozeman L., Burman W., Metchock B., Welch L., and Weiner M. Clin. Infect. Dis. 40 (2002) 386
6. Anquetin G., Greiner J., Mahmoudi N., Santillana-Hayat M., Gozalbes R., Farhati K., Derouin F., Aubry A., Cambau E., and Vierling P. Eur. J. Med. Chem. 41 (2006) 1478
7. Janin Y.L. Bioorg. Med. Chem. 15 (2007) 2479
8. Sriram D., Yogeeswari P., Basha S.J., Radha D.R., and Nagaraja V. Bioorg. Med. Chem. 13 (2005) 5774
9. Sriram D., Aubry A., Yogeeswari P., and Fisher L.M. Bioorg. Med. Chem. Lett. 16 (2006) 2982
10. Ginsburg A.S., Grosset J.H., and Bishai W.R. Lancet Infect. Dis. 3 (2003) 432
11. Aubry A., Veziris N., Cambau E., Truffot-Pernot C., Jarlier V., and Fisher L.M. Antimicrob. Agents Chemother. 50 (2006) 104
12. Cheng A.F., Yew W.W., Chan E.W., Chin M.L., Hui M.M., and Chan R.C. Antimicrob. Agents Chemother. 48 (2004) 596
13. Mitscher L.A., Sharma P.N., Chu D.T.W., Shen L.L., and Pernets A.G. J. Med. Chem. 30 (1987) 2283
14. 8): calcd C, 50.75; H, 3.41; N, 14.79; found C, 50.62; H, 3.47; N, 14.78.
15. National Committee for Clinical Laboratory Standards. Antimycobacterial susceptibility testing for Mycobacterium tuberculosis. Proposed standard M24-T. National Committee for Clinical Laboratory Standards, Villanova, PA, 1995.
16. Gundersen L.L., Meyer N.J., and Spilsberg B. J. Med. Chem. 45 (2002) 1383
17. Manjunatha U.H., Dalal M., Chatterji M., Radha D.R., Visweswariah S.S., and Nagaraja V. Nucleic Acids Res. 30 (2002) 2144
18. Mayne T.N., Johnson N.J., Kluwe W.M., Lencoski D.L., and Polzer R.J. J. Antimicrob. Chemother. 39 (1997) 67-73